Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
IMMUNOMEDICS (IMMU)
Last immunomedics earnings: 2/27 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
immunomedics.com/2017/immunomedics-announces-presentations-investor-event-2017-san-antonio-breast-cancer-symposium
Company Research
Source: GlobeNewswire
Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile Full Data will be Reported in Oral Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Company to Host Investor Event on June 3, 2018 MORRIS PLAINS, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a science-based and innovation-focused biopharmaceutical company committed to the development and worldwide commercialization of its unique and proprietary antibody-drug conjugate (ADC) platform, today announced that sacituzumab govitecan, its lead investigational ADC, induced promising objective responses as a single agent in heavily pre-treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). “For women with HR+ metastatic breast cancer relapsing after endocrine treatment, t
Show less
Read more
Impact Snapshot
Event Time:
IMMU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMMU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMMU alerts
High impacting IMMUNOMEDICS news events
Weekly update
A roundup of the hottest topics